Menu

Home / Guides / Tirzepatide vs. Ozempic

Two medicines. Different approvals.

Tirzepatide vs. Ozempic (2026): What Each Is Approved for, and What Each Costs

By the NexLife Medical Team · Medically reviewed by Adam Kennah, MD (NPI 1144260043) · Updated

For type 2 diabetes, tirzepatide is Mounjaro and semaglutide is Ozempic; head to head, A1c fell 2.0 to 2.3 points on tirzepatide vs. 1.9 on Ozempic 1 mg (SURPASS-2, 2021). Ozempic isn’t approved for weight loss; for weight, the approved tirzepatide is Zepbound. Self-pay, Ozempic is $349 a month up to 1 mg and $499 at 2 mg, and Mounjaro is $499 at every dose (checked Nov. 15, 2026). For weight loss, compounded tirzepatide at NexLife, which isn’t FDA-approved or Zepbound, is $115 a month on the 12-month plan, or $129 month to month.

$115/mo on 12 months, every dosePrice Match Guarantee†

  • Ozempic: type 2 diabetes, with heart and kidney uses
  • Tirzepatide: Mounjaro for diabetes, Zepbound for weight and sleep apnea
  • Head to head: SURPASS-2 (2021), in adults with type 2 diabetes
Published by NexLifeLegitScript-certified
NexLifeSame price at every dose
Illustration of a compounded tirzepatide vial

$115/mo on a 12-month plan, all-inclusive, same price at every dose

Or $129/mo month to month

Brand-name Zepbound, for weight: $299 to $449 a month at LillyDirect, by dose; $449 (7.5 to 15 mg) needs a refill within 45 days, or it’s $499 to $699

Check my eligibility

About 3 minutes of health questions · No insurance needed · Not prescribed? No charge for medication

See all 4 plans and what a year costs
Compounded tirzepatide, all in, the same price at every dose
PlanPer month12 months at this rate
12-month Most savings$115$1,380
6-month$119$1,428
3-month$125$1,500
Month to month$129$1,548

Month to month costs $168 more over 12 months than the 12-month plan. Month to month is billed monthly. The 3-, 6- and 12-month plans are paid upfront at checkout ($375, $714 or $1,380), and only if you’re prescribed. Plans renew until you cancel.

Price Match Guarantee†. Paying less elsewhere? We match your regular monthly price. How it works

4.8 out of 5 on Trustpilot, 407 reviews (read Nov. 15, 2026)LegitScript-certified

Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. The vial shown is an illustration. Always use the strength on your pharmacy’s label.

  • Licensed U.S. providers
  • LegitScript certified
  • Free expedited shipping
  • HSA, FSA, Affirm, Klarna, Afterpay
  • 24/7 support, real people
  • Filled by Absolute Pharmacy (Lutz, FL) or Boudreaux’s New Drug Store (Lake Charles, LA)

Compounded tirzepatide isn’t FDA-approved, isn’t Mounjaro or Zepbound, and wasn’t studied in their trials.

At a glance

Tirzepatide vs. Ozempic at a glance: 6 quick answers

Tirzepatide and Ozempic in six questions. Each one is explained below.

Tirzepatide vs. Ozempic: the short answers, from the Mounjaro, Zepbound and Ozempic labels, SURPASS-2 (2021), LillyDirect, NovoCare and Medicare.gov, checked November 1, 2026
QuestionAnswer
The same medicine?No. Tirzepatide (Mounjaro, Zepbound) acts on GIP and GLP-1 receptors; Ozempic’s semaglutide acts on GLP-1 only.
Approved for weight loss?Tirzepatide is, as Zepbound. Ozempic is FDA-approved for type 2 diabetes, so using it for weight loss is off-label.
Head to head?In SURPASS-2 (2021), adults with type 2 diabetes lowered A1c and weight more on each tirzepatide dose than on Ozempic 1 mg.
Heart and kidneys?Both labels have a heart-risk use in type 2 diabetes; only Ozempic’s adds a kidney use.
Self-pay price?Ozempic: $349 a month up to 1 mg, $499 at 2 mg. Mounjaro: $499. Zepbound: $299 to $449 by dose; $449 (7.5 to 15 mg) needs a refill within 45 days, or it’s $499 to $699.
Medicare’s $50 Bridge?Of these, only Zepbound’s KwikPen, if you qualify. It doesn’t cover Ozempic or Mounjaro, or people with type 2 diabetes.

LillyDirect and NovoCare prices re-checked Nov. 15, 2026; Medicare facts checked Nov. 1, 2026. The trials studied FDA-approved Mounjaro and Ozempic; compounded tirzepatide wasn’t studied.

  1. Tell us about you About 3 minutes of health questions
  2. A licensed provider decides You’re prescribed only if it’s right for you
  3. Your partner pharmacy ships Usually within 1 to 2 business days, free

Key takeaways

  • Tirzepatide did better head to head: A1c fell 2.0 to 2.3 points vs. 1.9 on Ozempic 1 mg (SURPASS-2, 2021).
  • Ozempic isn’t approved for weight loss: it’s FDA-approved for type 2 diabetes; for weight, the approved tirzepatide is Zepbound.
  • SURPASS-2 didn’t test Ozempic’s 2 mg top dose, and its weight results come from people with type 2 diabetes.
  • Heart and kidneys: Mounjaro’s and Ozempic’s labels have a heart-risk use in type 2 diabetes; only Ozempic’s adds a kidney-disease use.
  • Self-pay, Ozempic costs less than Mounjaro below 2 mg: $349 a month vs. $499 (checked Nov. 15, 2026).
  • At NexLife, compounded tirzepatide is $115 a month on the 12-month plan. It isn’t FDA-approved or a diabetes treatment.

At a glance

How are tirzepatide and Ozempic different?

Tirzepatide acts on two hormone receptors and Ozempic’s semaglutide on one. Ozempic is FDA-approved for type 2 diabetes, not weight loss; tirzepatide is Mounjaro for diabetes and Zepbound for weight. Self-pay, Ozempic is $349 a month up to 1 mg and Mounjaro $499 (checked Nov. 15, 2026).

Who this comparison is for: adults with type 2 diabetes choosing or switching between the two diabetes brands, Mounjaro (tirzepatide, from Eli Lilly) and Ozempic (semaglutide, from Novo Nordisk). Comparing the medicines for weight loss without diabetes? Our tirzepatide vs. semaglutide guide covers Zepbound, Wegovy and their SURMOUNT-5 trial. On another weekly diabetes shot? See Trulicity vs. tirzepatide.

From the labels (Mounjaro and Zepbound revised August 2026, Ozempic May 2026), LillyDirect, NovoCare, CMS and Medicare.gov, checked November 15, 2026. Side effects come from each label’s own trials, not a head-to-head.
Tirzepatide (Mounjaro, Zepbound)Ozempic (semaglutide)
Who makes itEli LillyNovo Nordisk
How it worksActivates two hormone receptors, GIP and GLP-1Activates one, GLP-1
FDA-approved forchecked November 1, 2026Mounjaro: type 2 diabetes in adults and children 10 and older, and lowering heart risk in adults with type 2 diabetes at high risk. Zepbound: weight loss in adults with obesity, or overweight with a weight-related condition, and sleep apnea with obesityType 2 diabetes in adults, and lowering heart risk (with heart disease) and kidney risk (with chronic kidney disease) in adults who have it. Not weight loss: using it for that is off-label
How you take itA weekly shot: single-dose pens for Mounjaro at LillyDirect; a 4-dose KwikPen or vials for ZepboundA weekly shot from a pen or a single-dose prefilled syringe. Daily Ozempic tablets are also sold, for type 2 diabetes
Weekly dose rangeon the labels2.5 mg to start, up to 15 mg0.25 mg to start, up to 2 mg
The head-to-head trialSURPASS-2, 2021, 40 weeksA1c down 2.0 to 2.3 points weight down 7.6 to 11.2 kg, on 5 to 15 mgA1c down 1.9 points weight down 5.7 kg, on 1 mg
Common side effectsvs. placebo, from each labelMounjaro 15 mg: nausea 18% (4%), diarrhea 17% (9%), vomiting 9% (2%)Ozempic 1 mg: nausea 20.3% (6.1%), diarrhea 8.8% (1.9%), vomiting 9.2% (2.3%)
Self-pay price, a monthchecked Nov. 15, 2026Mounjaro $499 at every dose; Zepbound $299 to $449 by dose, and its $449 (7.5 to 15 mg) needs a refill within 45 days, or it’s $499 to $699 (LillyDirect)$349 at 0.25 to 1 mg, $499 at 2 mg (NovoCare); $199 for each of a new patient’s first two fills through December 31, 2026
Insurance and Medicare2026 and 2027Type 2 diabetes: your plan or Part D. Zepbound for weight varies by plan; Medicare’s Bridge covers its KwikPen at $50 a month if you qualifyType 2 diabetes: your plan or Part D. The list price falls to $675, and Medicare’s $274 negotiated price starts, on January 1, 2027

NexLife Price Match Guarantee†. Already on compounded tirzepatide or semaglutide with another licensed provider, and paying less? We match your regular monthly price. How it works

Swipe the table sideways to see every column.

From the labels (Mounjaro and Zepbound revised August 2026, Ozempic May 2026), LillyDirect, NovoCare, CMS and Medicare.gov, checked November 15, 2026. Side effects come from each label’s own trials, not a head-to-head.

Which fits you

Tirzepatide or Ozempic: which fits your situation?

Choosing between tirzepatide and Ozempic depends on what you’re treating, your other health conditions and your coverage. Here are the usual starting points.

  • If you have type 2 diabetes

    Both are approved for it, and in SURPASS-2 (2021) tirzepatide lowered A1c more than Ozempic 1 mg. Your provider also weighs your kidneys, your heart, your other medicines and your coverage.

  • If weight loss is the goal

    Neither Ozempic nor Mounjaro is approved for it, so using either for weight alone is off-label. The FDA-approved forms of these two medicines for weight are Zepbound and Wegovy, semaglutide’s weight brand. Zepbound is $299 to $449 a month at LillyDirect by dose (its $449, at 7.5 to 15 mg, needs a refill within 45 days, or it’s $499 to $699); the Wegovy pen is $349 at NovoCare.

  • If you also have kidney disease

    Ozempic is the one with a kidney use: lowering the risk of kidney failure, worsening kidney function and heart-related death in adults with type 2 diabetes and chronic kidney disease.

  • If cost is the barrier

    Self-pay, Ozempic is $349 a month at most doses and Mounjaro $499. If your plan covers either one for diabetes, the maker’s savings card can bring a fill to as little as $25.

  • If needles are the problem

    Ozempic tablets, 1.5, 4 or 9 mg, are a daily pill for type 2 diabetes, $149 to $299 a month at NovoCare. FDA-approved tirzepatide comes only as a weekly shot.

  • If your coverage changes on January 1, 2027

    Ozempic’s list price falls to $675 that day, which can lower costs tied to list price, such as coinsurance. LillyDirect lists no 2027 change for Mounjaro or Zepbound (November 1, 2026).

Your provider decides. These are starting points, not a plan: the right choice depends on your health history, your other medicines and your coverage.

Step by step

How do you choose between tirzepatide and Ozempic?

Start with what you’re treating, then weigh the evidence, your heart and kidneys, side effects and cost.

  1. Start with what you’re treating. For type 2 diabetes, both are approved: Ozempic, and tirzepatide as Mounjaro. For weight loss, the approved tirzepatide is Zepbound; Ozempic or Mounjaro for weight alone is off-label, and a plan can refuse it.
  2. Weigh the head-to-head trial. In SURPASS-2 (2021), adults with type 2 diabetes lowered A1c and weight more on each tirzepatide dose than on Ozempic 1 mg. It didn’t test Ozempic’s 2 mg dose, and compounded tirzepatide wasn’t studied.
  3. Match the labels to your heart and kidneys. Mounjaro’s and Ozempic’s labels both have a heart-risk use in type 2 diabetes; only Ozempic’s adds a kidney-disease use. Zepbound has neither.
  4. Compare side effects. Both mostly cause nausea, diarrhea and vomiting, more often at higher doses. Nausea hit 18% on Mounjaro 15 mg (4% on placebo) and 20.3% on Ozempic 1 mg (6.1%), in separate trials.
  5. Compare self-pay prices. Ozempic is $349 a month, or $499 at 2 mg; Mounjaro is $499; Zepbound is $299 to $449 by dose, and its $449 (7.5 to 15 mg) needs a refill within 45 days, or it’s $499 to $699 (checked Nov. 15, 2026).
  6. Let your provider decide. A licensed provider weighs your health history, medicines and coverage. Switching takes a new prescription with no dose conversion, and Zepbound’s label doesn’t recommend taking it with any GLP-1, the class Ozempic belongs to.

NexLife’s providers prescribe compounded tirzepatide for weight loss; it isn’t a treatment for type 2 diabetes and doesn’t replace Ozempic or Mounjaro.

Head to head

Mounjaro vs. Ozempic for type 2 diabetes: what did SURPASS-2 find?

Each tirzepatide dose lowered A1c and weight more than Ozempic 1 mg over 40 weeks: A1c fell 2.0 to 2.3 points vs. 1.9, in 1,879 adults with type 2 diabetes on metformin. SURPASS-2 (2021) is the one trial that compared them; it didn’t test Ozempic’s 2 mg top dose.

SURPASS-2 (New England Journal of Medicine, 2021; first reported by Lilly on March 4, 2021): 1,879 adults with type 2 diabetes on metformin, 40 weeks, open-label. From Mounjaro’s label (revised August 2026), section 14.3, read November 1, 2026. Pounds are our conversion.
Ozempic 1 mgTirzepatide 5 mgTirzepatide 10 mgTirzepatide 15 mg
A1c change, in pointsfrom 8.3% at the start−1.9−2.0−2.2−2.3
Extra A1c drop vs. Ozempic—0.20.40.5
Reached an A1c under 7%79%82%86%86%
Weight changekg, with pounds−5.7 kg 12.6 lb−7.6 kg 16.8 lb−9.3 kg 20.5 lb−11.2 kg 24.7 lb
Extra weight loss vs. Ozempickg—1.93.65.5

Swipe the table sideways to see every column.

SURPASS-2 (New England Journal of Medicine, 2021; first reported by Lilly on March 4, 2021): 1,879 adults with type 2 diabetes on metformin, 40 weeks, open-label. From Mounjaro’s label (revised August 2026), section 14.3, read November 1, 2026. Pounds are our conversion.

Who was in it. Adults with type 2 diabetes, average age 57 and average BMI 34, after 8.6 years with diabetes. Blood sugar was the main goal, so the weight results come from people with diabetes.

The dose matters. SURPASS-2 gave Ozempic at 1 mg. Its label now goes up to 2 mg, a dose this trial didn’t include, so it can’t say how 2 mg compares.

For weight loss without diabetes, the head-to-head trial is SURMOUNT-5 (2025). It compared Zepbound with Wegovy, not with Ozempic; its results are in our tirzepatide vs. semaglutide guide.

These trials studied FDA-approved Mounjaro, Ozempic, Zepbound and Wegovy; compounded tirzepatide wasn’t studied.

Heart and kidneys

Do tirzepatide and Ozempic protect the heart and kidneys?

On heart risk, both: Mounjaro’s and Ozempic’s labels now include a heart-risk use for adults with type 2 diabetes. On kidneys, only Ozempic’s label adds a kidney-disease use (labels checked November 15, 2026). Mounjaro’s label was revised in August 2026, Ozempic’s in May 2026.

The details
Ozempic: heartLowering the risk of heart attack, stroke and heart-related death in adults with type 2 diabetes and heart disease, based on the SUSTAIN 6 trial (2016).
Ozempic: kidneysLowering the risk of worsening kidney function, kidney failure and heart-related death in adults with type 2 diabetes and chronic kidney disease, based on the FLOW trial (2024).
Mounjaro: heartAdded in August 2026: lowering the risk of heart attack, stroke and heart-related death in adults with type 2 diabetes at high risk. It rests on SURPASS-CVOT (2025), which compared Mounjaro with dulaglutide, the medicine in Trulicity. More in Trulicity vs. tirzepatide.
Ozempic tabletsThe heart use, for adults with type 2 diabetes at high risk, with no kidney use listed.
ZepboundNeither: it’s approved for weight loss and for sleep apnea with obesity.

The labels don’t rank them. Each use comes from a trial against placebo or another medicine, not against each other.

Side effects

Which has more side effects, tirzepatide or Ozempic?

Tirzepatide and Ozempic side effects are alike: mostly nausea, diarrhea and vomiting, more often at higher doses. No label compares them directly.

Each column comes from a different label’s placebo-controlled trials: Mounjaro’s and Ozempic’s in type 2 diabetes, Zepbound’s in obesity. Not head-to-head. Labels read November 1, 2026.
Side effectMounjaro 15 mgOzempic 1 mgZepbound 15 mg
Nausea18% (placebo 4%)20.3% (placebo 6.1%)28% (placebo 8%)
Diarrhea17% (placebo 9%)8.8% (placebo 1.9%)23% (placebo 8%)
Vomiting9% (placebo 2%)9.2% (placebo 2.3%)13% (placebo 2%)
Constipation7% (placebo 1%)3.1% (placebo 1.5%)11% (placebo 5%)
Abdominal pain5% (placebo 4%)5.7% (placebo 4.6%)10% (placebo 5%)

Swipe the table sideways to see every column.

Each column comes from a different label’s placebo-controlled trials: Mounjaro’s and Ozempic’s in type 2 diabetes, Zepbound’s in obesity. Not head-to-head. Labels read November 1, 2026.

Slow steps are built in. Both medicines start low and step up no faster than every 4 weeks: tirzepatide from 2.5 mg, Ozempic from 0.25 mg.

Higher in the weight trials. Zepbound’s rates run higher than Mounjaro’s at the same dose, in trials that enrolled different people for a different goal.

What to expect, and what helps: tirzepatide side effects.

Cost

What do tirzepatide and Ozempic cost in 2026?

Self-pay, Ozempic is $349 a month at most doses, Mounjaro $499 and Zepbound $299 to $449 by dose; Zepbound’s $449 (7.5 to 15 mg) needs a refill within 45 days, or it’s $499 to $699 (checked November 15, 2026). With coverage, savings cards can bring your copay to $25.

Makers’ and TrumpRx.gov prices, savings terms, CMS and Medicare.gov, checked November 1, 2026: medication only, a 28-day fill a month. NexLife’s price includes your provider and shipping.
How you payTirzepatide (Mounjaro, Zepbound)Ozempic
Insurance and a savings cardcommercial plans that cover itAs little as $25 a fill, for up to 3 months, with Lilly’s Mounjaro or Zepbound pen card. The Zepbound card ends December 31, 2026As little as $25 a fill, for up to 3 months, with up to $100 off a month
The maker’s self-pay pharmacyLillyDirect, NovoCareMounjaro $499 a month at every dose. Zepbound $299 at 2.5 mg, $399 at 5 mg, $449 from 7.5 to 15 mg with a refill within 45 days, otherwise $499 at 7.5 mg and $699 at 10 to 15 mg$349 from 0.25 to 1 mg, $499 at 2 mg. New patients: $199 for each of two starter fills, if the prescription reaches NovoCare by December 31, 2026
TrumpRx.govself-pay listingsZepbound vials starting at $299, ordered through LillyDirectThe same Ozempic prices as NovoCare, with a coupon at a pharmacy
Medicare Part Dfor an approved usePlans can cover Mounjaro for type 2 diabetes and Zepbound for sleep apneaPlans can cover it for type 2 diabetes. From January 1, 2027, Medicare pays a negotiated $274 for 30 days; that isn’t your copay
Medicare GLP-1 Bridgeweight loss, if you qualifyZepbound KwikPen only: $50 a month through December 31, 2027, not with type 2 diabetesNot covered by the Bridge
Compounded, through NexLifefor weight loss; not FDA-approved$115 a month on the 12-month plan $129 month to month, at every dose. Compounded tirzepatide isn’t FDA-approved, and it isn’t Mounjaro or Zepbound$95 a month on the 12-month plan $109 month to month. Compounded semaglutide isn’t FDA-approved, and it isn’t Ozempic

Swipe the table sideways to see every column.

Makers’ and TrumpRx.gov prices, savings terms, CMS and Medicare.gov, checked November 1, 2026: medication only, a 28-day fill a month. NexLife’s price includes your provider and shipping.

What a year costs, paying yourself

Our math from the prices above: a brand year is 13 four-week fills; a NexLife year is 12 monthly payments month to month, or one upfront payment on the 12-month plan. Compounded tirzepatide is a different product, not FDA-approved. At NexLife it’s prescribed for weight loss; it isn’t a treatment for type 2 diabetes.
If you pay yourselfA monthA year
Ozempic, 0.25 to 1 mgNovoCare, 13 four-week fills$349$4,537
Ozempic, a new patient’s first yearfirst two fills at $199 each through December 31, 2026, then $349$199, then $349$4,237
Mounjaro, any doseLillyDirect, 13 fills$499$6,487
Zepbound, stepping up from 2.5 mg$299, $399, then 11 fills at $449 from 7.5 mg, each refill within 45 days, or $499 to $699 otherwise$299 to $449$5,637
NexLife,compounded tirzepatide, 12-month plan$115$1,380
NexLife,compounded tirzepatide, month to month$129$1,548

Swipe the table sideways to see every column.

Our math from the prices above: a brand year is 13 four-week fills; a NexLife year is 12 monthly payments month to month, or one upfront payment on the 12-month plan. Compounded tirzepatide is a different product, not FDA-approved. At NexLife it’s prescribed for weight loss; it isn’t a treatment for type 2 diabetes.

NexLife Price Match Guarantee†. Already on compounded tirzepatide or semaglutide with another licensed provider, and paying less? We match your regular monthly price. How it works

Covered for type 2 diabetes? A $25 savings-card fill of Ozempic or Mounjaro costs less than any self-pay price. NexLife’s providers prescribe compounded tirzepatide for weight loss. It isn’t a treatment for type 2 diabetes and doesn’t replace Ozempic, Mounjaro or your diabetes care.

Paying yourself for weight loss? $5,837 a year for Zepbound at 7.5 mg or more (13 fills of $449, each refill within 45 days; otherwise $499 at 7.5 mg and $699 at 10 to 15 mg) vs. $1,380 on NexLife’s 12-month plan, a difference of $4,457 a year. Compounded tirzepatide is a different product: it isn’t FDA-approved, and a licensed provider prescribes it only when it offers a significant difference for you. Paying less for it elsewhere? Our Price Match Guarantee† matches your regular monthly price.

Every Zepbound price, dose by dose: Zepbound cost without insurance. Side by side with compounded: compounded vs. brand-name tirzepatide.

Coverage

Does insurance cover tirzepatide or Ozempic?

For type 2 diabetes, plans and Medicare drug plans can cover both Ozempic and Mounjaro. For weight loss, Zepbound is the tirzepatide approved for it, and coverage varies by plan.

  • Coverage follows the label

    Plans decide coverage by use. Ozempic and Mounjaro are approved for type 2 diabetes, so a prescription for weight alone is off-label, and a plan can refuse it.

  • Medicare drug plans

    Part D plans can cover Ozempic and Mounjaro for type 2 diabetes, and Zepbound for sleep apnea. They don’t cover drugs used only for weight loss; the Bridge, a separate CMS program, is the exception.

  • The Medicare GLP-1 Bridge

    $50 a month for Wegovy, Foundayo or the Zepbound KwikPen, through December 31, 2027, for people with Part D who qualify. People with type 2 diabetes aren’t eligible; their Part D plan may cover a GLP-1 instead.

  • What changes in 2027

    On January 1, 2027, Ozempic’s list price falls to $675 and Medicare’s negotiated price for semaglutide starts. Tirzepatide isn’t on Medicare’s negotiation lists for 2027 or 2028.

“You aren’t eligible for the Medicare GLP-1 Bridge, because your Medicare drug plan should cover GLP-1 medications to treat these conditions.”

Medicare.gov, Weight loss drugs, on people with type 2 diabetes, moderate to severe sleep apnea or fatty liver disease

Who the $675 helps. People whose costs follow the list price, such as coinsurance or a deductible not yet met. Novo says its self-pay prices don’t change.

What else changes on January 1: GLP-1 coverage in 2027. Who qualifies for the $50: Medicare and GLP-1s. If your plan said no: what to do when coverage ends.

Switching

Can you switch from Ozempic to Mounjaro or Zepbound?

Yes, with a new prescription and your provider’s plan. There’s no official dose conversion between them.

  1. A new prescription

    Going from Ozempic to Mounjaro or Zepbound means a new medicine and a new prescription. Both tirzepatide labels start at 2.5 mg a week for 4 weeks.

  2. No dose conversion

    Neither label turns an Ozempic dose into a tirzepatide dose. Your provider decides where you start and how fast you step up.

  3. Not both at once

    Zepbound’s label says taking it with any GLP-1 receptor agonist, the class Ozempic belongs to, isn’t recommended. Semaglutide’s half-life is about a week, so your provider sets the day of your first tirzepatide dose.

  4. Other diabetes medicines

    With insulin or a sulfonylurea, both labels warn that low blood sugar is more likely, and the labels say a lower dose of those medicines can lower the risk. Your provider decides.

“Coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended.”

Eli Lilly and Company, Zepbound (tirzepatide) prescribing information, revised August 2026

On birth control pills? The tirzepatide labels advise switching to a non-oral method, or adding a barrier method, for 4 weeks after you start and for 4 weeks after each dose increase.

Timing, the first weeks and what to tell your provider: switching from semaglutide to tirzepatide.

Warnings

What are the warnings for tirzepatide and Ozempic?

Both carry the same boxed warning about thyroid tumors, the same reasons not to take them, and a similar list of serious side effects (labels read November 15, 2026). Their common side effects are alike too: mostly nausea, diarrhea and vomiting, more often at higher doses.

  • The boxed warning, on both. Tirzepatide and semaglutide caused thyroid C-cell tumors in rodents; it isn’t known whether they do in people. Neither is for anyone with a personal or family history of medullary thyroid carcinoma (MTC), or anyone with MEN 2.
  • Who else shouldn’t take them. Anyone who’s had a serious allergic reaction to the medicine or its ingredients. All three labels, Mounjaro’s, Zepbound’s and Ozempic’s, also say they aren’t recommended with severe gastroparesis.
  • Serious side effects on both labels. Pancreatitis, gallbladder disease, kidney injury from dehydration, severe stomach reactions, serious allergic reactions, eye complications in people with diabetic retinopathy, and low blood sugar with insulin or a sulfonylurea.
  • Sudden vision loss. The FDA warned on Nov. 9, 2026, that GLP-1 medicines may raise the risk of NAION, a rare optic nerve problem that can cause sudden, painless vision loss in one eye; call your provider right away if that happens (FDA).
  • Before surgery. Both labels warn about breathing stomach contents into the lungs under anesthesia or deep sedation, so tell your care team you take it.
  • Pregnancy. Ozempic’s label says to stop at least 2 months before a planned pregnancy. Mounjaro’s says to use it in pregnancy only if the benefit justifies the risk. Zepbound’s says to stop it when a pregnancy is recognized.

Call a doctor right away for severe stomach pain that won’t go away, which may spread to your back, with or without vomiting (the labels say to stop the medicine if pancreatitis is suspected); a lump or swelling in your neck, hoarseness or trouble swallowing; signs of a serious allergic reaction; or vomiting and diarrhea that leave you dehydrated.

Never share a pen: Ozempic’s label says so for its pens, and Mounjaro’s for its KwikPen. Questions about a side effect? Call or text (949) 818-8000, 24/7.

At NexLife

What do you get with compounded tirzepatide at NexLife?

You get a licensed provider, a nutrition plan, a 1:1 coaching call, free expedited shipping and 24/7 support, at the same price for every dose, from $115 a month on the 12-month plan to $129 month to month. Compounded tirzepatide isn’t FDA-approved and isn’t Mounjaro or Zepbound.

Compounded tirzepatide is a different product from Mounjaro and Zepbound, and it isn’t FDA-approved. Here’s what comes with it at NexLife.

“This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.”

U.S. Food and Drug Administration, Compounding and the FDA: Questions and Answers
The details
What you pay$115 a month on the 12-month plan, $119 on 6 months, $125 on 3 months, or $129 month to month. The same price at every dose, with no membership fee.
What’s includedA licensed provider who follows your dose, the medication, a nutrition plan, a 1:1 coaching call, free expedited shipping and real people 24/7. Your prescription is filled by Absolute Pharmacy (Lutz, FL) or Boudreaux’s New Drug Store (Lake Charles, LA), our two state-licensed 503A partner pharmacies.
Who decidesA licensed provider reviews your health history and medicines online and prescribes only if it’s right for you. Not prescribed? No charge for medication.
Price Match Guarantee†Paying less for compounded tirzepatide or semaglutide with another licensed U.S. telehealth provider or clinic? Send a receipt from the last 60 days, and we match your regular monthly price. Not open to people with Medicare, Medicaid or TRICARE.
How to payNexLife takes HSA and FSA cards and provides a letter of medical necessity if your plan asks for one; Affirm, Klarna or Afterpay are offered at checkout. People with Medicare can pay for themselves.
What we don’t doNexLife’s providers prescribe compounded tirzepatide and semaglutide only, not Mounjaro, Zepbound or Ozempic, and NexLife doesn’t bill insurance. If your plan covers a brand for you, that can cost less.

What happens next. A 3-minute online assessment, then a licensed provider’s review. If you’re prescribed, your partner pharmacy ships, usually within 1 to 2 business days. NexLife has 4.8 out of 5 on Trustpilot, 407 reviews (read Nov. 15, 2026), and is LegitScript-certified; Adam Kennah, MD, is its medical director.

Vial math

How many units is your semaglutide dose?

Your semaglutide dose in units depends on your vial’s strength. Here are the Wegovy label’s dose steps at two example strengths.

Semaglutide dose steps from the Wegovy label, with the volume and units on a U-100 syringe at two example strengths, 2.5 mg/mL and 5 mg/mL
WeeksWeekly doseAt 2.5 mg/mLAt 5 mg/mL
1 to 40.25 mg0.1 mL (10 units)0.05 mL (5 units)
5 to 80.5 mg0.2 mL (20 units)0.1 mL (10 units)
9 to 121 mg0.4 mL (40 units)0.2 mL (20 units)
13 to 161.7 mg0.68 mL (68 units)0.34 mL (34 units)
17 onward2.4 mg0.96 mL (96 units)0.48 mL (48 units)

The math: mL = dose ÷ strength (mg per mL); units = mL × 100. At 2.5 mg/mL, 1 mg is 1 ÷ 2.5 = 0.4 mL, or 40 units. At 5 mg/mL, the same 1 mg is 0.2 mL, or 20 units.

Both strengths are examples only. The same dose is a different number of units at a different strength, so read the strength on your own vial’s label. Your prescription sets your dose and schedule, which may differ from these label steps. Every step: the semaglutide dosage chart. Or enter your own vial’s strength in the semaglutide dosage calculator.

Loved by our members

Real stories from NexLife members about their care and service.

A selection of 5-star reviews from Trustpilot, quoted in full as written. Results vary from person to person, and weight loss isn’t guaranteed.

★★★★★TrustScore 4.8 out of 5 on Trustpilot407 reviews as of Nov. 15, 2026 · Read them all ↗

  • ★★★★★Read on Trustpilot ↗

    “Great communication. Easy to work with. They work to set you up for success.”

    Anthony C.

  • ★★★★★Read on Trustpilot ↗

    “Fast delivery and easy to get a hold of when needing to talk with someone!”

    Browneyes

  • ★★★★★Read on Trustpilot ↗

    “So happy with NexLife. Communication has been great, I’m recommending them to all my friends.”

    April

  • ★★★★★Read on Trustpilot ↗

    “Excellent visit. Dr. Kennah was very knowledgeable and helpful and answered all my questions.”

    Ethan B.

  • ★★★★★Read on Trustpilot ↗

    “That’s a real site with good prices and plans!”

    Estefany L.

  • ★★★★★Read on Trustpilot ↗

    “Affordable, quick and easy. They could not have made it a smoother less stressful experience.”

    Andisheh K.

  • ★★★★★Read on Trustpilot ↗

    “Fast service great communication!! Willing to work with you!”

    Bon

  • ★★★★★Read on Trustpilot ↗

    “Great service and excellent communication!”

    Gabrielle D.

  • ★★★★★Read on Trustpilot ↗

    “Easy and pricing not bad! Customer service was helpful in answering my questions.”

    Lyndy T.

  • ★★★★★Read on Trustpilot ↗

    “Good experience, great team”

    Mai S.

  • ★★★★★Read on Trustpilot ↗

    “Great communciation and was fast and reliable”

    Kiki

  • ★★★★★Read on Trustpilot ↗

    “Very happy so far”

    Tammy E.

Names are shortened for privacy. Reviews are members’ opinions, not medical advice.

What does NexLife cost?
One flat price at every dose.

No membership fee. Provider care, a nutrition plan, coaching and shipping are included. Paying less with another licensed provider? We match your regular monthly price.†

Illustration of a compounded tirzepatide vialGIP + GLP-1

12-month plan $115/mo

Tirzepatide

Weekly and dual-action. Care, coaching and shipping included. On a 12-month plan, $1,380 paid upfront; $129/mo month to month, billed monthly.

Check my eligibility

Compounded, not FDA-approved · Not prescribed? No charge for medication

Illustration of a compounded semaglutide vialGLP-1

12-month plan $95/mo

Semaglutide

Weekly GLP-1. Care, coaching and shipping included. On a 12-month plan, $1,140 paid upfront; $109/mo month to month, billed monthly.

Check my eligibility

Compounded, not FDA-approved · Not prescribed? No charge for medication

TrustScore 4.8 out of 5 on Trustpilot 407 reviews as of Nov. 15, 2026 · Read them all ↗

Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. Vials shown are illustrations. Always use the strength on your pharmacy’s label. Every plan and price · Price Match Guarantee† terms

The NexLife Price Match Guarantee†

Paying less elsewhere?
Keep your price. Upgrade your care.

Already on compounded tirzepatide or semaglutide? Pay less with another licensed U.S. telehealth provider or clinic, and we match your regular monthly price for as long as your plan stays active.† Plus a provider who follows your dose, a nutrition plan, a coaching call and real people 24/7.

  1. 1Send a receipt from the last 60 days
  2. 2A NexLife provider reviews your prescription
  3. 3Pay your matched price, at every dose
Switch and keep my price

Locked while your plan is activeSame price at every doseNo membership fee

†Terms: see the Price Match Guarantee† details below. Compounded medications aren’t FDA-approved; a provider prescribes one only when it offers a significant difference for you.

Tirzepatide vs. Ozempic: your questions

Fair questions about NexLife

Will my price go up with my dose?
No. You pay the same at every dose.
What if I’m not prescribed?
You aren’t charged for medication.
Can I cancel?
Yes, by email. It takes effect 30 days after we receive it. Plans renew until you cancel; our cancellation policy has the details.
Do I need insurance?
No. Pay with an HSA or FSA card, or with Affirm, Klarna or Afterpay at checkout.

Is tirzepatide the same as Ozempic?

No. Tirzepatide (Mounjaro, Zepbound) is Lilly’s GIP and GLP-1 medicine; Ozempic is Novo Nordisk’s semaglutide, which acts on GLP-1 only. Ozempic is FDA-approved for type 2 diabetes, so using it for weight loss is off-label; Zepbound is the tirzepatide approved for weight loss. Semaglutide’s weight-loss brand is Wegovy.

Can you take tirzepatide and Ozempic together?

No. Zepbound’s label says taking it with any GLP-1 receptor agonist, the class Ozempic belongs to, isn’t recommended. If you move from one to the other, your provider tells you when to stop Ozempic and when to take your first tirzepatide dose.

Can I switch from Ozempic to Mounjaro or Zepbound?

Yes, with a new prescription. Both tirzepatide labels start at 2.5 mg a week for 4 weeks, and neither converts an Ozempic dose, so your provider decides where you start. If you take insulin or a sulfonylurea, those doses may need to come down.

Is Ozempic cheaper than Mounjaro without insurance?

Yes, except at 2 mg, where both are $499. NovoCare’s self-pay price for Ozempic is $349 a month from 0.25 to 1 mg; LillyDirect’s for Mounjaro is $499 at every dose (checked Nov. 15, 2026). With commercial coverage for type 2 diabetes, either maker’s savings card can bring a fill to as little as $25.

Does insurance cover Ozempic or Mounjaro for type 2 diabetes?

It can: type 2 diabetes is the use both are approved for, and Medicare drug plans can cover them too. With commercial coverage, each maker’s savings card can bring a fill of up to 3 months to as little as $25. Government beneficiaries can’t use the cards.

Is there an Ozempic pill or a tirzepatide pill?

There’s an Ozempic pill: Novo sells Ozempic tablets, 1.5, 4 or 9 mg, for type 2 diabetes, at $149 to $299 a month through NovoCare (checked November 15, 2026). FDA-approved tirzepatide comes only as a shot. Foundayo, Lilly’s daily pill, is a different medicine, orforglipron.

Does Mounjaro protect the heart and kidneys like Ozempic?

For the heart, its label now does: since August 2026 it’s approved to lower heart attack, stroke and heart-related death risk in adults with type 2 diabetes at high risk. For the kidneys, no. Only Ozempic’s label has a kidney-disease use.

Does Mounjaro cause more nausea than Ozempic?

Not clearly, and no label compares them head to head. In each label’s own diabetes trials, nausea hit 18% on Mounjaro 15 mg (4% on placebo) and 20.3% on Ozempic 1 mg (6.1% on placebo). Both mostly cause stomach side effects: nausea, diarrhea and vomiting. These trials studied FDA-approved Mounjaro and Ozempic; compounded tirzepatide wasn’t studied.

Does Mounjaro lower A1C more than Ozempic?

In SURPASS-2 (2021), yes, at the doses tested. Over 40 weeks in adults with type 2 diabetes, A1C fell 2.0 to 2.3 points on tirzepatide 5 to 15 mg and 1.9 on Ozempic 1 mg, and weight fell 7.6 to 11.2 kg vs. 5.7 kg. The trial didn’t test Ozempic 2 mg. These trials studied FDA-approved Mounjaro and Ozempic; compounded tirzepatide wasn’t studied.

I take Ozempic for type 2 diabetes. Should I ask about Mounjaro?

Your prescriber decides, but here’s what they’ll weigh. In SURPASS-2, tirzepatide 5 to 15 mg lowered A1C 2.0 to 2.3 points vs. 1.9 on Ozempic 1 mg over 40 weeks. Both labels include a heart-risk use in type 2 diabetes; only Ozempic’s adds kidney disease. Self-pay, Mounjaro is $499 a month and Ozempic $349 below 2 mg (checked Nov. 15, 2026).

How much is Ozempic for a new patient without insurance?

At NovoCare, a new patient pays $199 for each of the first two Ozempic fills, if the prescription reaches NovoCare by December 31, 2026. After that, it’s $349 a month from 0.25 to 1 mg, or $499 at 2 mg (checked Nov. 15, 2026).

Will Ozempic’s price change in 2027?

Its list price falls to $675 on January 1, 2027, which can lower costs tied to list price, such as coinsurance. Novo says its self-pay prices don’t change. Medicare’s negotiated $274 for 30 days also starts that day; that isn’t your copay.

Does Medicare’s GLP-1 Bridge cover Ozempic or tirzepatide?

Of these, only the Zepbound KwikPen: $50 a month through December 31, 2027, for people with Part D who qualify. The Bridge doesn’t cover Ozempic or Mounjaro, and people with type 2 diabetes aren’t eligible; their Part D plan may cover a GLP-1 instead.

Important safety information

Compounded tirzepatide and semaglutide are not FDA-approved, and the FDA hasn’t reviewed them for safety, effectiveness or quality. A provider prescribes them only when they offer a significant difference for you compared with an FDA-approved product. Both medicines may cause thyroid tumors, including cancer: don’t use either if you or a family member has had medullary thyroid carcinoma (MTC), or if you have multiple endocrine neoplasia syndrome type 2 (MEN 2). The most common side effects include nausea, diarrhea, vomiting, constipation and stomach pain.

Read the full safety information

In studies with rodents, both medicines caused thyroid tumors; it isn’t known whether they cause them in people. Tell your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. Serious side effects can include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, severe stomach problems, serious allergic reactions, vision changes in people with type 2 diabetes, and a faster heart rate. The FDA warned on Nov. 9, 2026, that GLP-1 medicines may raise the risk of NAION, a rare eye condition that can cause sudden vision loss in one eye; call your provider right away if that happens (FDA). Tell your care team before any surgery or procedure that uses anesthesia or deep sedation. Don’t combine either medicine with other GLP-1 medicines.

Tirzepatide can make birth control pills less effective: switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after you start and for 4 weeks after each dose increase. Both medicines may harm an unborn baby. Semaglutide should be stopped at least 2 months before a planned pregnancy. Tell your provider right away if you’re pregnant, planning to be, or breastfeeding.

This is a summary, not the complete safety information. Read the full Prescribing Information for FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy), and talk with your provider. You can report side effects to the FDA at 1-800-FDA-1088 or fda.gov/medwatch.

† NexLife Price Match Guarantee: for new NexLife members switching from a licensed U.S. telehealth provider or clinic with an active prescription for compounded tirzepatide or semaglutide. We match your regular all-in monthly price there (medication plus any required membership, program or visit fee, on a month-to-month plan); first-month offers, coupons, referral credits and prepaid multi-month rates aren’t matched. Proof from the last 60 days required. A licensed provider must determine that treatment is right for you. Not open to people with Medicare, Medicaid or TRICARE coverage. Full terms.

About NexLife. NexLife is a telehealth and care-coordination platform. Care is delivered through affiliated, physician-owned medical groups, and licensed providers decide whether treatment is right for you. NexLife doesn’t make or compound medication: state-licensed partner pharmacies fill each prescription, and we coordinate the rest. Available only in states where our affiliated providers are licensed.

Who wrote and medically reviewed this page?

Adam Kennah, MDMedical Director, NexLife · Board-certified in emergency medicine (American Board of Emergency Medicine) · NPI 1144260043

Leads the NexLife Medical Team, which writes and medically reviews NexLife’s guides, including this one.

NexLife Medical TeamWrites and updates NexLife’s guides

Labels, TrumpRx.gov listings and Medicare figures checked Nov. 1, 2026; makers’ self-pay prices re-checked Nov. 12, 2026.

  • How we checked. Every approval, dose, warning and side-effect rate comes from the current prescribing information: Mounjaro and Zepbound (revised August 2026) and Ozempic (revised May 2026), read November 15, 2026. The NAION warning comes from the FDA’s Nov. 9, 2026, safety communication. SURPASS-2’s results come from Mounjaro’s label, section 14.3. Prices come from LillyDirect, NovoCare Pharmacy, TrumpRx.gov and the makers’ savings terms, and Medicare facts from CMS and Medicare.gov, all checked November 1, 2026; LillyDirect’s and NovoCare’s prices were re-checked on Nov. 12, 2026. Ozempic’s 2027 list price is from Novo Nordisk’s February 24, 2026 announcement. We list announced prices only, and we don’t forecast them. Zepbound, Mounjaro, Foundayo, KwikPen, LillyDirect and Trulicity are trademarks of Eli Lilly and Company; Ozempic, Rybelsus, Wegovy and NovoCare of Novo Nordisk. NexLife isn’t affiliated with either.
  • Every fact, sourced. Each price and rule links to the page it comes from.
  • How we make money. NexLife is a telehealth and care-coordination platform. We earn revenue when people join NexLife.
  • Corrections, fast. See something wrong or out of date? Email hello@nexlife.us and we’ll fix it.
  • How we work. How we review programs · GLP-1 price index · Is NexLife legit? · States NexLife serves

Paying less elsewhere? We match it.†

You know how they compare. Next: a 3-minute check.

A licensed provider reviews your history and decides if compounded tirzepatide is right for you: $115 a month on the 12-month plan, or $129 month to month, at every dose.

4.8 out of 5 on Trustpilot, 407 reviews (read Nov. 15, 2026) · Medical director Adam Kennah, MD (NPI 1144260043) · LegitScript-certified

Compounded medications aren’t FDA-approved. A provider prescribes one only when it offers a significant difference for you.

  1. 1
    Tell us about you

    Start online with your health history.

  2. 2
    A licensed provider decides

    Online, following your state’s rules. You’re prescribed only if treatment is right for you.

  3. 3
    We ship it, then stay with you

    Our partner pharmacy usually ships within 1 to 2 business days. Free shipping, and questions come to us 24/7, never to the pharmacy.

Sources

  1. Mounjaro (tirzepatide) prescribing information, Eli Lilly, revised August 2026. Read November 15, 2026.
  2. Zepbound (tirzepatide) prescribing information, Eli Lilly, revised August 2026. Read November 15, 2026.
  3. Ozempic (semaglutide) prescribing information, Novo Nordisk, revised May 2026. Read November 15, 2026.
  4. NovoCare Pharmacy: Ozempic and Wegovy self-pay prices and terms. Checked November 15, 2026.
  5. NovoCare: Ozempic self-pay terms (prices by dose; new-patient offer; FDA-approved uses only). Read Nov. 15, 2026.
  6. NovoCare: Price your Wegovy (pen, Wegovy HD and pill self-pay prices). Read Nov. 15, 2026.
  7. Novo Nordisk: Ozempic patient brochure with savings card terms (May 2026). Read November 1, 2026.
  8. TrumpRx.gov: Ozempic pen. Checked November 15, 2026.
  9. TrumpRx.gov: Zepbound vial. Checked November 15, 2026.
  10. LillyDirect: Mounjaro self-pay prices. Checked Nov. 15, 2026.
  11. LillyDirect: Zepbound self-pay prices. Checked Nov. 15, 2026.
  12. Eli Lilly: Zepbound full terms and conditions (savings cards). Read November 15, 2026.
  13. Eli Lilly: Mounjaro savings card. Checked November 15, 2026.
  14. Novo Nordisk: US list price reduction for Wegovy, Ozempic and Rybelsus (February 24, 2026). As read for our Wegovy 2027 guide, November 1, 2026.
  15. CMS: Medicare drug price negotiation, negotiated prices for 2027 (fact sheet). Read November 1, 2026.
  16. CMS: Medicare drug price negotiation, selected drugs for 2028 (fact sheet). Read November 1, 2026.
  17. CMS: Medicare GLP-1 Bridge. Read Nov. 15, 2026.
  18. Medicare.gov: Weight loss drugs (the Medicare GLP-1 Bridge). Read November 15, 2026.
  19. SURPASS-2: Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med, 2021. Results as stated in Mounjaro’s label.
  20. Eli Lilly: SURPASS-2 topline results, tirzepatide vs. semaglutide 1 mg (March 4, 2021). Read November 1, 2026.
  21. PharmaTimes: Lilly’s tirzepatide beats Ozempic in head-to-head type 2 diabetes trial (June 28, 2021). Read November 1, 2026.
  22. SURMOUNT-5: Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med, 2025. As cited on our tirzepatide vs. semaglutide guide.
  23. FLOW: semaglutide in type 2 diabetes and chronic kidney disease (Perkovic V, et al., N Engl J Med 2024;391:109-121), American College of Cardiology trial summary. Read November 1, 2026.
  24. SURPASS-CVOT: Nicholls SJ, et al. Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med 2025;393:2409-2420. Citation as given by the American College of Cardiology, read October 25, 2026; results as stated in Mounjaro’s label.
  25. FDA: Compounding and the FDA, questions and answers.
  26. NexLife: pricing, every plan.